WeLeader Biomedical (7713) reported revenue of NT$112.6 million for Oct 2026, +15.3% year on year and -3.4% from the previous month. Revenue for Jan–Oct 2026 was NT$1.08 billion (+18.8% year on year).
Year-on-year revenue growth: 21 months in a row. →
In Oct 2026, it ranked No. 68 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$112.6 million | +15.3% | -3.4% |
| Sep 2026 | NT$116.6 million | +16.8% | +0.3% |
| Aug 2026 | NT$116.2 million | +14.8% | -3.2% |
| Jul 2026 | NT$120 million | +26.4% | +6.3% |
| Jun 2026 | NT$112.9 million | +15.2% | +1.4% |
| May 2026 | NT$111.3 million | +20.6% | -3.2% |
| Apr 2026 | NT$115 million | +38.8% | +12.3% |
| Mar 2026 | NT$102.3 million | +14.3% | +30.6% |
| Feb 2026 | NT$78.3 million | +4.6% | -20.3% |
| Jan 2026 | NT$98.3 million | +21.7% | +1.8% |
| Dec 2025 | NT$96.6 million | +21.0% | -4.3% |
| Nov 2025 | NT$100.9 million | +14.7% | +3.3% |
| Oct 2025 | NT$97.7 million | +22.0% | -2.1% |
| Sep 2025 | NT$99.8 million | +25.8% | -1.4% |
| Aug 2025 | NT$101.2 million | +10.2% | +6.6% |
| Jul 2025 | NT$94.9 million | +12.5% | -3.1% |
| Jun 2025 | NT$97.9 million | +0.1% | +6.1% |
| May 2025 | NT$92.3 million | +14.9% | +11.5% |
| Apr 2025 | NT$82.8 million | +11.3% | -7.5% |
| Mar 2025 | NT$89.5 million | +6.3% | +19.6% |
| Feb 2025 | NT$74.9 million | +10.7% | -7.3% |
| Jan 2025 | NT$80.7 million | -2.9% | +1.1% |
| Dec 2024 | NT$79.8 million | +1.5% | -9.2% |
| Nov 2024 | NT$88 million | +15.2% | +9.8% |
| Oct 2024 | NT$80.1 million | +5.9% | +1.0% |
Jan–Oct 2026 cumulative: NT$1.08 billion (+18.8% YoY)
Other Biotech & Medical companies
Compare with peers: WeLeader Biomedical vs PEC / WeLeader Biomedical vs Lotus Pharm / WeLeader Biomedical vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16